Suzhou Industrial Park listed firms hit $177 billion in market value
The park said it hosts 74 listed companies, with several of them having crossed the 100-billion-yuan market-cap level.
Tag: biopharma
Read More
Suzhou BioBAY drives $26.6B in overseas biopharma deals in Jan-May
The growth is fueled by high-value strategic partnerships and the park’s focus on proprietary intellectual property.
Zhejiang targets RMB 500B biopharma sector, bets on BCI
A central focus is the development of brain-computer interfaces (BCIs), particularly in neurorehabilitation. The policy calls for leveraging national AI pilot platforms to accelerate clinical deployment.